Bendamustine moves forward for multiple myeloma in Japan
This article was originally published in Scrip
Executive Summary
SymBio Pharmaceuticals has begun a Phase II clinical trial in Japan with its lead product candidate, bendamustine, for the treatment of multiple myeloma (MM).